Filing Flows › Pure Bioscience (PURE) › Q1 FY26
Pure Bioscience (PURE) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Dec 15, 2025
Pure Bioscience (PURE) reported revenue of $707K for the first quarter fiscal 2026 (Q1 FY26), +27% from a year earlier and -7% from the quarter before. Operating margin was -53.6%, net loss $464K (65.6% of revenue).
Pure Bioscience, Q1 FY26: revenue $707K (+27% year over year), operating margin -53.6%, net loss $464K, operating cash flow −$250K. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $707K | -7% | +27% |
| Operating profit | −$379K | — | — |
| Net earnings | −$464K | — | — |
| Operating cash flow | −$250K | — | — |
What changed
Revenue was $707K in Q1 FY26, up 27% year over year and down 7% from the previous quarter. Product was the largest line at 100% of revenue. Product added $152K year over year (up 27%), 100% of the total change.
Gross margin was 63.6%, up 5.1 points from a year earlier. Operating costs exceeded revenue by $379K, an operating margin of -53.6%. Operating expenses fell 13% while revenue rose 27%. The fastest-growing cost line was Research & development (+21%). The quarter ended with a net loss of $464K, wider than the previous quarter's $332K loss.
Operating cash flow was −$250K. Non-cash charges added back $1K of depreciation and $34K of share-based compensation. Working capital and other items added $179K.
Questions
What was Pure Bioscience's revenue in the first quarter fiscal 2026?
Pure Bioscience (PURE) reported revenue of $707K for the first quarter fiscal 2026 (Q1 FY26), +27% from a year earlier and -7% from the quarter before.
Was Pure Bioscience profitable in the first quarter fiscal 2026?
Operating loss was $379K (-53.6% of revenue) and net loss $464K.
Source: Pure Bioscience 10-Q on SEC EDGAR.